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Abstract
Although endometrial cancer is the most common cancer of the female reproductive tract, we have little
understanding of what controls endometrial cancer beyond the transcriptional effects of steroid hormones such as
estrogen. As a result, we have limited therapeutic options for the ~62,000 women diagnosed with endometrial cancer
each year in the United States. Here, in an attempt to identify new prognostic and therapeutic targets, we focused on
a new area for this cancer—alternative mRNA splicing—and investigated whether splicing factor, SF3B1, plays an
important role in endometrial cancer pathogenesis. Using a tissue microarray, we found that human endometrial
tumors expressed more SF3B1 protein than non-cancerous tissues. Furthermore, SF3B1 knockdown reduced in vitro
proliferation, migration, and invasion of the endometrial cancer cell lines Ishikawa and AN3CA. Similarly, the SF3B1
inhibitor, Pladienolide-B (PLAD-B), reduced the Ishikawa and AN3CA cell proliferation and invasion in vitro. Moreover,
PLAD-B reduced tumor growth in an orthotopic endometrial cancer mouse model. Using RNA-Seq approach, we
identiﬁed ~2000 differentially expressed genes (DEGs) with SF3B1 knockdown in endometrial cancer cells. Additionally,
alternative splicing (AS) events analysis revealed that SF3B1 depletion led to alteration in multiple categories of AS
events including alternative exon skipping (ES), transcript start site usage (TSS), and transcript termination site (TTS)
usage. Subsequently, bioinformatics analysis showed KSR2 as a potential candidate for SF3B1-mediated functions in
endometrial cancer. Speciﬁcally, loss of SF3B1 led to decrease in KSR2 expression, owing to reduced maturation of KSR2
pre-mRNA to a mature RNA. Importantly, we found rescuing the KSR2 expression with SF3B1 knockdown partially
restored the cell growth of endometrial cancer cells. Taken together, our data suggest that SF3B1 plays a crucial
oncogenic role in the tumorigenesis of endometrial cancer and hence may support the development of SF3B1
inhibitors to treat this disease.

Introduction
In 2020, endometrial cancer is expected to be newly
diagnosed in approximately 65,620 patients, and 12,590
women are predicted to die from this disease in the
United States, making it the most common gynecologic
malignancy1. With the rise of obesity—a strong risk factor
for endometrial cancer—the number of cases are expected
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to double by 20302. Although most endometrial cancer
patients present with low-grade, estrogen-driven, type 1,
early-stage disease and have a favorable prognosis, those
with advanced-stage, hormone-independent, type 2,
metastatic disease have few treatment options and poor
survival outcomes. Currently, major treatment options
include endocrine therapy, chemotherapy, immunotherapy, radiotherapy, and hysterectomy. However, endocrine
therapy is not widely used because of its limited efﬁcacy,
and hysterectomy is not a suitable option for women who
wish to preserve fertility. Developing new therapeutic
options will require a greater understanding of genes that
contribute to endometrial cancer progression.
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Recent work in several cancers has revealed that dysregulation of splicing factors can lead to the generation of
abnormal mature transcripts3 that drive tumorigenesis4–7.
For example, mutations in U2AF1, SRSF2, ZRSR2, and
SF3B1 have been identiﬁed in myelodysplastic syndromes,
chronic lymphocytic leukemia, uveal melanoma, and
breast cancer8–19. In endometrial cancer, the SF3B1 is one
of the frequently mutated splicing factor20,21. SF3B1 is a
core component of the U2 small nuclear ribonucleoprotein, which speciﬁcally recognizes the 3′ splice site at
intron–exon junctions22,23. In endometrial cancer and
several other cancers, SF3B1 appears to act as an oncogene, as most of the mutations occur in hotspots20.
Besides, overexpression of SF3B1 has also been reported
to drive tumorigenesis in several cancers, including breast
cancer, prostate cancer, and myelodysplastic syndromes24–26. Moreover, a recent study revealed that
knock down of overexpressed SF3B1 expression reduced
breast cancer cell proliferation, migration, and invasion26.
However, whether SF3B1 overexpression likewise promotes endometrial cancer progression is unknown.
Here, we report that SF3B1 protein is overexpressed in
human endometrial tumor samples and endometrial
cancer cell lines. Further, we show that knockdown of
SF3B1 or treatment with the SF3B1 inhibitor
Pladienolide-B reduces cell viability, migration, and
invasion of endometrial cancer cells in vitro and endometrial tumor cell growth in vivo. Finally, we report that
knockdown of SF3B1 alters mRNA maturation of the
kinase suppressor of Ras gene KSR2 and KSR2 acts as a
downstream mediator of SF3B1 function(s) in endometrial cancer. Thus, SF3B1 protein expression may be a
prognostic biomarker and a therapeutic target for treating
endometrial cancer patients.

Female athymic nude mice (6–8 weeks of age; Jackson
Laboratory) were maintained under pathogen-free conditions with food and water provided ad libitum.
The sample size of animal experiment was chosen based
on the preliminary experiments and similar well-designed
experiments, and no statistical method was used. Investigators were blinded to the treatment groups during data
collection and subsequent data analysis. Before surgery,
animals received intramuscular 0.1 mg/kg buprenorphine
hydrochloride (Temgesic, Reckitt Benckiser, Berkshire,
UK) for analgesia. Mice were anesthetized with 100 mg/kg
ketamine and 5 mg/kg xylazine and placed on a heating
pad in dorsal decubitus. Their dorsal skin was cleaned and
sterilized with betadine, and a 0.5-cm incision was made in
the right lower ﬂank to expose the right uterine horn. A
single-cell suspension of 50 μl of ice-cold Matrigel (BD
Matrigel Basement Membrane Matrix, BD Biosciences, San
Jose, CA) containing 2 × 106 AN3CA cells was injected into
the endometrial cavity through the myometrium by using a
0.3 mm insulin syringe (Omnican 50; B-Braun, Melsungen,
Germany). The needle was retracted after waiting for a few
seconds to allow the Matrigel cell suspension to polymerize
and to prevent leakage into the abdominal cavity. The
uterine horn was returned to its original position, and the
incision was closed with staples. After the surgery, animals
were placed in a warm environment and supervised until
full recovery. Three weeks later, mice were randomly
assigned to receive either 10 mg/kg PLAD-B (n = 4) or
vehicle (DMSO) (n = 4) intraperitoneally on days 0, 2, 4,
and 6. Animals were weighed weekly. Two weeks after the
last dose, the mice were sacriﬁced, and the tumors were
imaged, weighed, and processed for histological analysis
and immunoﬂuorescence.

Materials and methods

Co-transfection experiment

Mouse and human study approval

Lipofectamine 2000 (Invitrogen) was used to cotransfect Ishikawa cells with SF3B1 siRNA or Control
siRNA and pEGFPC1-hKSR2 or pEGFPC1-empty vector.
After 36 h, cells were counted and re-plated in 96-well
plates, and the relative proliferation rate was evaluated
with the MTT proliferation kit at 0, 24, and 48 h.
Experiments were performed in triplicates.

Animal studies were performed according to a protocol
(#20160227) approved by the Institutional Animal Care and
Use Committee of Washington University School of Medicine, Saint Louis, MO, USA. Human volunteers provided
written informed consent in accordance with an Institutional Review Board-approved protocol (#201612127) from
Washington University School of Medicine and the guidelines of the Declaration of Helsinki.
Cell culture

The human endometrial cancer cell lines Ishikawa
(Sigma, St. Louis, MO) and AN3CA, KLE, and RL-95-2
(all from American Type Culture Collection) were purchased and used within 6–8 months. All cells were
maintained in MEM/DMEM medium supplemented with
10% fetal bovine serum at 37 °C and 5% CO2.

Ofﬁcial journal of the Cell Death Differentiation Association

Orthotopic endometrial cancer model

Statistics

A two-tailed paired Student’s t-test was used to test for
statistical signiﬁcance, deﬁned as P < 0.05. One-way analysis of variance (ANOVA) was used for multiple group
comparisons. Asterisks represent the level of signiﬁcance:
*P = 0.05, **P = 0.01, ***P = 0.001, and ****P = 0.0001.
A detailed description of the materials and methods
used in this study is available in the online Supplementary
Material.
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Results
SF3B1 expression is elevated in endometrial cancer

To investigate whether SF3B1 was involved in endometrial tumorigenesis, we ﬁrst examined its expression in
a tissue microarray containing 102 human endometrial
cancer samples of various tumor grades. SF3B1 expression
was higher in grades I, II, and III endometrial tumors than
in normal endometrial tissues (Fig. 1a, b). Importantly, we
observed a grade-dependent increase in SF3B1 expression
with the highest expression in Grade III tumors. The
distribution of cases with higher SF3B1 expression as
follows: Grade I, 26/34 (76%), Grade II, 34/36 (94%), and
Grade III, 27/27 (100%). Consistent with this, we found
that tumors in a genetic mouse model of endometrial
cancer (PRCre/+Ptenﬂox/ﬂox) overexpress SF3B1 protein
(Fig. 1c). Next, we compared SF3B1 mRNA and protein
expression in primary human endometrial epithelial cells
(our experimental control) and three Type 1 endometrial
cancer cell lines: Ishikawa cells (isolated from a welldifferentiated tumor), RL-95-2 cells (from a moderately
differentiated tumor), and AN3CA cells (from a metastatic undifferentiated tumor). Additionally, we examined
SF3B1 expression in one Type II endometrial cancer cell
line, KLE (from a poorly differentiated tumor). Although
SF3B1 mRNA was only elevated in KLE cells, SF3B1
protein was more highly expressed in Ishikawa, AN3CA,
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and KLE cells than in control cells (Fig. 1d). Importantly,
we performed full exon sequencing of SF3B1 in Ishikawa,
AN3CA, and RL-95-2 cells (data not shown) and found no
SF3B1 missense mutations in any of these cell lines. These
data indicate that endometrial cancer cell lines overexpress SF3B1 protein in the absence of mutations or
elevated mRNA overexpression. Together, these results
demonstrate that SF3B1 expression is elevated in endometrial cancer at protein level.
SF3B1 is required for endometrial cancer cell proliferation
and cell cycle progression

Given that SF3B1 expression was elevated in endometrial cancers, we wondered whether SF3B1 promotes
endometrial cancer cell proliferation. To investigate this,
we transiently transfected Ishikawa and AN3CA cells (the
cell lines in which SF3B1 was most highly expressed) with
control or SF3B1-targeted small interfering RNA (siRNA).
Western blotting and quantitative real-time PCR (Fig. 2a,
d) conﬁrmed that the siRNA substantially reduced SF3B1
protein and mRNA expression. After 48 h, we re-plated
the cells and followed proliferation for 72 h and found
that SF3B1 siRNA signiﬁcantly decreased the proliferation
of Ishikawa and AN3CA cells (Fig. 2b, e). In addition,
clonogenic assays revealed that SF3B1 knockdown
reduced Ishikawa cells proliferation by 84% and AN3CA

Fig. 1 SF3B1 is overexpressed in endometrial cancer cells. a Representative images (×40) of immunohistochemical SF3B1 staining (brown) of
control and endometrial cancer tissues in an endometrial carcinoma tissue array. b Quantitative analysis of SF3B1 expression in normal, grade I, II, and
III endometrial tissue samples scored according to staining intensity and number of positive cells [low (score ≤ 5) or high (score ≥ 5)]. Statistical
signiﬁcance was assessed using one-way analyses of variance (ANOVA) and data are presented as mean ± SEM. ***P < 0.001, ****P < 0.0001.
c Representative immunoﬂuorescence images of SF3B1 staining (green) of uterine tissues from 3-month-old Ptenf/f or PRCre/+Ptenf/f (Pten cKO) mice,
which spontaneously develop endometrial carcinoma one month after birth. d SF3B1 transcript and protein levels in normal human endometrial
epithelial cells (HEEC) and indicated endometrial cancer (EC) cell lines. GAPDH used as a protein loading control.
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Fig. 2 SF3B1 enhances endometrial cancer cell proliferation. a, d SF3B1 protein and transcript levels of SF3B1 in Ishikawa (a) and AN3CA (d) cells
transfected with control siRNA or SF3B1 siRNA. b, e Representative MTT proliferation assays in Ishikawa (b) and AN3CA (e) cells. c, f Representative
clonogenic assays (left) and quantitation (right) in Ishikawa (c) and AN3CA (f) cells. Data are presented as mean ± SEM. n = 3; ***P < 0.001,
****P < 0.0001.

cell proliferation by 81% (Fig. 2c, f). These results suggested that SF3B1 promotes endometrial cancer cell
proliferation.
Next, we evaluated the effect of SF3B1 knockdown on
cell cycle progression. Flow cytometry analysis revealed
that, compared to cells transfected with control siRNA, a
much greater proportion of Ishikawa and AN3CA cells in
which SF3B1 was knocked down were arrested in the G2/
M phase of the cell cycle, with a concomitant reduction in
the percentage of cells in the G1 phase (Fig. 3a, b, d, e).
These results were consistent with ﬁndings of Dolatshed
et al.25 that SF3B1 knockdown caused G2/M cell cycle
arrest in hematopoietic stem and progenitor cells in
myelodysplastic syndrome. Next, we examined the
expression of the cell cycle regulatory proteins: Cyclin D1
(required throughout the cycle), Cyclin E1 (S-phase transition), Cyclin B1 (transition from G2 to M), p21 (cell cycle
inhibitor), CDK4 (progression through G1 phase), and
CDK2 (progression through G1 phase)27. Expression of
Cyclins B1, E1, and D1 was efﬁciently reduced in cells in
Ofﬁcial journal of the Cell Death Differentiation Association

which SF3B1 was knocked down, whereas the expression
of p21 was elevated (Fig. 3c, f). These results suggested
that SF3B1 silencing reduced Ishikawa and AN3CA cell
proliferation by inducing G2/M cell cycle arrest.
SF3B1 is required for tumor cell migration and invasion

Metastasis, which occurs after cells undergo the
epithelial-to-mesenchymal transition (EMT), is the leading
cause of most cancer-related deaths28–31. To undergo EMT,
tumor cells must reduce their expression of E-cadherin and
increase the expression of vimentin to become capable of
migrating and invading other tissues28–31. To determine
whether SF3B1 was required for tumor cell migration, we
transfected Ishikawa and AN3CA cells with SF3B1 siRNA
or control siRNA, conﬁrmed that SF3B1 mRNA expression
was efﬁciently knocked down (Fig. 4a, e), and then performed wound-healing scratch assays. At 48 h post-scratch,
Ishikawa and AN3CA cells expressing SF3B1 siRNA were
signiﬁcantly less migratory than cells expressing control
siRNA (Fig. 4b, f). The migration capacity of SF3B1

Popli et al. Cell Death and Disease (2020)11:842
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Fig. 3 Loss of SF3B1 causes G2/M cell cycle arrest in endometrial cancer cells. a, d Ishikawa and AN3CA cells transfected with control or SF3B1
siRNA for 72 h and then subjected to ﬂow cytometry analysis of cell cycle. Histograms depict the percentages of cells in each phase of the cell cycle.
b, e Graphs representing the distribution of cells in indicated phases of the cell cycle. c, f Western blotting of cell cycle regulatory proteins in Ishikawa
(c) and AN3CA (f) cells transfected with control or SF3B1 siRNA. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

Fig. 4 SF3B1 promotes tumor cell migration and invasion. a, e Conﬁrmation of SF3B1 mRNA depletion in Ishikawa and AN3CA cells transfected
with Control or SF3B1 siRNA. b, f Representative scratch assays in Ishikawa (b) and AN3CA (f) cells transfected with control or SF3B1 siRNA.
c, g Representative microscopic images (×10) of Ishikawa (c) and AN3CA (g) cells that invaded through the transwell in the matrigel invasion assay.
d, h Expression analysis of proteins associated with cell migration and invasion. Data are presented as mean ± SEM. **P < 0.01, ****P < 0.0001.

depleted Ishikawa and AN3CA when calculated was
70–80% less than their control siRNA cells respectively
(Fig. 4b, f).
To evaluate whether SF3B1 was required for invasion, we
performed an assay in which cells transfected with SF3B1
siRNA or Control siRNA were placed into the upper
chamber of matrigel-coated transwells. We then stained
Ofﬁcial journal of the Cell Death Differentiation Association

the cells that invaded through the matrigel into the lower
chamber and found that, compared to cells transfected
with control siRNA, fewer cells transfected with SF3B1
siRNA were able to invade through matrigel (Fig. 4c, g).
Next, we examined the expression of adhesion markers:
E-cadherin and vimentin associated with EMT. We found
that cells in which SF3B1 was knocked down had higher
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E-cadherin expression and lower vimentin expression than
control siRNA-treated cells (Fig. 4d, h). Together, these
results suggest that SF3B1 promotes migration and invasion behaviors of endometrial cancer cells.
The SF3B1 inhibitor Pladienolide-B reduces endometrial
cancer cell proliferation, migration, and invasion in vitro

PLAD-B is a macrocyclic lactone originally obtained
from Streptomyces platensis Mer-11107, strain isolated
from a soil sample collected in Kanagawa, Japan (accession
number FERM P-18144; Bioconsortia Program Laboratory
National Institute of Advanced Industrial Science and
Technology, Japan)32–34. PLAD-B is spliceosome inhibitor
that speciﬁcally targets the SF3B1 spliceosome subunit35
and has anti-tumor activity in multiple cancers35,36. For
example, when immunocompromised mice were implanted with primary cultured cells from gastric cancer
patients, the tumors regressed with PLAD-B treatment36.
Thus, we determined the effect of PLAD-B on in vitro
proliferation, migration, and invasion of endometrial cancer cells. Both Ishikawa and AN3CA cells were treated with
vehicle or increasing concentrations of PLAD-B, and cell
proliferation was measured 0, 24, 48, and 72 h later. As
expected, PLAD-B substantially decreased the proliferation
of Ishikawa and AN3CA cells in a dose-dependent manner
with IC50 of ∼10 nM (p < 0.01) (Fig. 5a, e). Similarly, in
clonogenic assays, PLAD-B substantially reduced the clonal
growth of Ishikawa and AN3CA cells (Fig. 5b, f). Next, we
examined the effect of PLAD-B on cell migration and
invasion. Scratch assays revealed that PLAD-B reduced the
migration of Ishikawa cells by 60% and of AN3CA cells by
80% (Fig. 5c, g). In the invasion assay, Ishikawa and
AN3CA cells treated with PLAD-B failed to invade through
matrigel (Fig. 5d, h). These data indicate that PLAD-B
efﬁciently reduces the oncogenic potential of SF3B1 in
endometrial cancer cells. Additionally, we also evaluated
the effect of SF3B1 knockdown on KLE cells viability,
migration, and cell cycle progression and found the similar
effects as we observed in Ishikawa and AN3CA cells
(Fig. S1). Moreover, consistent with minimal SF3B1 protein
levels, RL-95-2 cells showed diminished impact of SF3B1
knockdown or PLAD-B treatment on cell viability and
migration in comparison to other three endometrial cancer
cells that have robust SF3B1 protein levels (Fig. S2).
Importantly, whereas SF3B1-depleted RL-95-2 cells are in a
growing phase still at 72 h, three other endometrial cancer
cell lines with high SF3B1 levels were in diminished cell
growth state (Fig. S2).
PLAD-B inhibits endometrial tumor growth in vivo

We next sought to assess the activity of PLAD-B in vivo
in an orthotopic model of endometrial cancer. AN3CA
cells (2 × 106) were injected into the right uterine horns of
mice, leaving the left uterine horns untreated as controls.
Ofﬁcial journal of the Cell Death Differentiation Association
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After 3 weeks, mice were randomized to receive either
vehicle (DMSO) or 10 mg/kg PLAD-B intraperitoneally
every other day for 1 week36. Two weeks later, mice were
euthanized and uteri were collected (Fig. 6a). In the
vehicle group, the tumor-cell-injected uterine horns were
~10 times larger than the control uterine horns (Fig. 6b,
left images). Histological evaluation revealed normal histology with intact endometrial glands in the left uterine
horn and a solid growing primary tumor in the right
uterine horn (Fig. 6b, left images). The tumors showed
characteristics of grade 3 endometrioid endometrial cancers, with areas of necrosis and myometrial invasion. In
the PLAD-B group, the control and tumor-cell-injected
horns were similar in size (Fig. 6b, right images). Additionally, the tumor-cell-injected horns in the PLAD-B
group had a typical uterine structure with intact endometrial glands (Fig. 6b, right images). However, we noted
the remnants of regressing tumors in the right uteri of
PLAD-B-treated mice (Fig. 6b, right images). Quantiﬁcation analysis showed that tumor weight reduced ~76% in
PLAD-B-treated mice compared to vehicle-treated mice
(Fig. 6b). These results suggest that PLAD-B effectively
reduced the tumor growth. However, PLAD-B appeared
to be non-toxic, as we did not notice any differences in
behavior, feeding habits, or mobility between vehicle- and
PLAD-B-treated mice (data not shown).
To begin to uncover how PLAD-B reduced tumor
growth, we examined the expression of proliferation marker Ki-67. In the control uterine horns of vehicle-treated
mice, Ki-67-positive cells were evident in the luminal and
glandular epithelium. The tumor-cell-injected uterine
horns had substantially more Ki-67-positive cells, indicating the growth of a solid tumor (Fig. 6c). The tumor-cellinjected horns in PLAD-B treated mice had substantially
fewer Ki-67-positive cells than the corresponding horns in
vehicle-treated mice (Fig. 6c) indicating that PLAD-B efﬁciently reduced tumor cell proliferation. PLAD-B also
appeared to inhibit normal cell proliferation, as we saw
fewer Ki-67-positive cells in the normal horns of PLAD-Btreated mice than in the corresponding horns of vehicletreated mice (Fig. 6c, right images).
We wondered whether PLAD-B affected SF3B1 expression and thus stained the uterine horns from the two
groups of mice with an SF3B1-speciﬁc antibody. In the
vehicle-treated mice, the tumor-cell-injected horns had
substantially higher SF3B1 expression than the corresponding normal horns (Fig. 6d). SF3B1 expression was
mainly restricted to the luminal and glandular epithelium
in control uteri (Fig. 6d). As expected, we did not notice
any difference in SF3B1 expression between the tumorcell-injected horns in the vehicle and the PLAD-B-treated
mice, indicating that PLAD-B inhibits SF3B1 activity but
not expression. Together, these ﬁndings suggest that SF3B1
could be targeted to reduce endometrial cancer growth.

Popli et al. Cell Death and Disease (2020)11:842
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Fig. 5 PLAD-B inhibits endometrial cancer cell growth in vitro. a, e MTT cell proliferation assay of cells treated with vehicle or increasing
concentrations of PLAD-B at indicated time points. b, f Representative clonogenic assays of cells treated with vehicle or PLAD-B for 10–14 days. The
right panel shows quantiﬁcation of stained colonies by spectrophotometry at 490 nm. c, g Wound-healing assay of Ishikawa and AN3CA cells treated
with vehicle or PLAD-B at 80–90% conﬂuence. The right panel shows quantiﬁcation of relative migrated area of vehicle- and PLAD-B-treated Ishikawa
and AN3CA cells. d, h Representative microscopic images of Ishikawa and AN3CA cells treated with vehicle or PLAD-B that invaded through the
transwell in the matrigel invasion assay. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Identiﬁcation of SF3B1-driven transcriptome and
alternative splicing events in endometrial cancer cells

Since overexpressed SF3B1 promotes endometrial
tumorigenesis both in vitro and in vivo, we next investigated the underlying mechanism. Toward this, we determined the SF3B1 transcriptome by performing RNA-seq
Ofﬁcial journal of the Cell Death Differentiation Association

analysis from Ishikawa cells depleted with SF3B1. As
shown in Fig. 7a, hierarchical clustering revealed a distinct
SF3B1-dependent transcriptome in in Ishikawa cells. Using
a 2.5-fold cutoff and Benjamini–Hochberg false discovery
rate (FDR) of <0.01 threshold for inclusion, we identiﬁed
1992 differentially expressed genes (DEGs) between
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Fig. 6 PLAD-B inhibits endometrial tumor growth in vivo. a Schematic representation of experimental procedure. b Representative images of
uteri from mice treated with vehicle or PLAD-B and H&E-stained uterine horns from vehicle- or PLAD-B-treated animals (left). Quantiﬁcation of tumor
weights from vehicle- or PLAD-B-treated mice at endpoint (Right). c, d Representative confocal immunoﬂuorescent cross-sectional images of uteri
from vehicle- or PLAD-B-treated animals stained for Ki-67 and SF3B1; scale bar: 200 μm. LE luminal epithelia, G glandular epithelia. Normal, control uninjected horn; tumor, AN3CA cell-injected uterine horn.

Control and SF3B1-depleted Ishikawa cells (Fig. 7c and
Supplementary Table 1). Further, Gene Ontology (GO)
enrichment analysis revealed that SF3B1 regulated DEGs
enriched in several biological processes, including cell
adhesion, angiogenesis, and cytokine production involved
in immune response, and ATP binding (Supplementary
Table 2). Importantly, pathway analysis has been shown
that much of the DEGs enriched in calcium signaling
pathway, Ras signaling, and metabolic pathways (Supplementary Table 2). This enrichment analysis suggests that
SF3B1 overexpression promotes pro-cancer-speciﬁc transcriptome in endometrial cancer.
Ofﬁcial journal of the Cell Death Differentiation Association

Further, to gain insight into the spectrum of genes that
are aberrantly spliced, we used DEXSeq to perform differential exon usage analysis of our RNA-seq data. DEXseq
analyzed 6,40,456 exons for differential exon usage. A
complete set of DEXseq raw counts, normalized counts,
and statistics for every exon is provided as Supplementary
Table 3 (annotations for each exon are provided in Supplementary Table 4). Summarization of the exons disrupted suggested that SF3B1 depletion leads to multiple
categories of alternative splicing including alternative exon
skipping (ES), transcript start site, and transcript termination site usage (Fig. 7d). A total of 3840 exons exhibited
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Fig. 7 (See legend on next page.)
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(see ﬁgure on previous page)
Fig. 7 SF3B1 depletion alters the transcriptome and AS events in EC cells. a Heat map of mRNAs differentially expressed between control and
SF3B1 knockdown Ishikawa cells with cutoff of FDR < 0.01 and logFC > 2.5; n = 3 each group. b MA plot showing the appropriate normalization of
RNA-seq data. c Volcano plots for all the DEGs in each comparison. The left side indicates downregulated genes and the right side indicates that
upregulated DEGs with p values < 0.05. d Summary of alternative exon usage by alternative transcription category. e Volcano density plot of exons’
FDR corrected adjusted p value and log2 fold change of SF3B1 knockdown vs. control. Color represents the density of each bin. Dashed lines
represent signiﬁcance thresholds. f Heat map depicting normalized counts for exons with sufﬁcient coverage. Color represents log2(x + 1)transformed normalized counts. g Exon usage and normalized counts for control and SF3B1 knockdown conditions for ENSG00000281398 [SNHG4].
Color (purple) in the gene map indicates signiﬁcant exons.

signiﬁcant loss or gain, determined by FDR corrected
adjusted p value cutoff of 0.01 and minimum log2 fold
change >2, which affected 2160 total gene loci (Fig. 7e).
Unsupervised hierarchical clustering was performed on
exons with sufﬁcient coverage and variance. Replicates in
the control and SF3B1 knockdown conditions clustered
together tightly, indicating a consistent and predictable
deregulation of normal splicing upon SF3B1 knockdown
(Fig. 7f). Speciﬁc novel alternative splicing events induced
by SF3B1 were readily identiﬁable and ranged from relative
simple alternative ES (e.g. Fig. 7g) to much more complex
patterns. Overall, the alternative splicing analysis revealed
wide scale disruption of alternative splicing across the
transcriptome.
Validation of DEGs identiﬁed by RNA sequencing

Given the wide scale alterations across transcriptome
with SF3B1 knockdown (Fig. 7a), next we aimed to ﬁnd a
speciﬁc DEGs that might be a candidate downstream
mediators of SF3B1 action. For this, we narrowed seven
DEGs based on their biological functions. Out of these
seven DEGs, ﬁve (KSR2, GJD3, TRAF1, TBC1D16, and
DOCK11) were downregulated and (FOXQ1, MYLK2) two
were upregulated (Fig. S3). First, we validated the
expression of these seven altered genes with SF3B1
knockdown in both Ishikawa and AN3CA cells (Fig. S3).
Since, Ras signaling is the primary mitogenic pathway of
endometrial cancer, we decided to focus on KSR2, a Ras
signaling promoting gene for subsequent studies (Fig. S4).
KSR2 is a molecular scaffold protein shown to be critical
in the integration of various mitogenic and metabolic
pathways37–39. As expected, we found SF3B1 regulated
the KSR2 expression in endometrial cancer cells both at
transcript and protein levels (Fig. 8a).
KSR2 contributes to SF3B1-dependent proliferation in
endometrial cancer cells

SF3B1 is an important regulator of pre-mRNA
machinery24,40,41 and we found that KSR2 transcript
levels were abrogated with SF3B1 knockdown (Fig. 8a).
Therefore, we wondered whether SF3B1 is required for
maturation of KSR2 pre-mRNA to mature mRNA. To test
this, we measured mature (spliced) and immature
(unspliced) KSR2 mRNAs using intron–exon and
Ofﬁcial journal of the Cell Death Differentiation Association

exon–exon junction-speciﬁc primers (Fig. 8b). While
knockdown of SF3B1 abrogated mature KSR2 mRNAs in
both Ishikawa and AN3CA cells, KSR2 pre-mRNAs
remained stable in Ishikawa cells and reduced modestly
in AN3CA cells (Fig. 8c). This reduced level of pre-mRNA
might be due to splicing coupled transcription defect42 or
due to reduced stability of pre-mRNA owing to intron
retention (splicing defect)43. Importantly, the relative ratio
of pre-mRNA/mRNA was signiﬁcantly higher with SF3B1
knockdown in both the Ishikawa and AN3CA cells,
indicating that the reduced splicing efﬁciency in the
absence of SF3B1 lead to an accumulation of pre-mature
KSR2 RNA. Finally, to determine whether KSR2 contributes to overall SF3B1 function, we performed a rescue
experiment by co-transfecting the Ishikawa cells with
siRNA and human KSR2 plasmid and determined the cell
proliferation. As expected, KSR2 protein levels abrogated
with SF3B1 knockdown restored with KSR2-GFP plasmid
transfection in Ishikawa cells (Fig. 8d). Importantly, rescuing the KSR2 protein in SF3B1-depleted cells partially
restored the reduced cell proliferation due to SF3B1
knockdown (Fig. 8e). Taken together, these data suggest
that SF3B1 exerts its functions by generating mature
splice variants and KSR2 is one such downstream effectors of SF3B1 function in endometrial cancers (Fig. 8f).

Discussion
Here, we present several pieces of evidence indicating
that the splicing factor SF3B1 plays an important role in
endometrial cancer pathogenesis. First, we found
increased SF3B1 protein expression in human endometrial tumors and three endometrial cancer cell lines.
This is consistent with multiple reports that showed an
elevated expression of the other splicing factors in several
human cancers8. Second, our in vitro data demonstrated
that SF3B1 promotes endometrial cancer cell proliferation, cell cycle progression, migration, and invasion.
Third, our in vivo data indicated that SF3B1 inhibitor,
PLAD-B, reduces endometrial tumor growth in mice.
Finally, we found that SF3B1 mediates pro-proliferative
function partially by driving KSR2 mRNA maturation.
In our study, decreased cell viability and associated cell
cycle regulators expression in SF3B1-depleted cells highlights its pro-proliferative role in endometrial cancer.

Popli et al. Cell Death and Disease (2020)11:842

Page 11 of 13

Fig. 8 SF3B1 regulates KSR2 mRNA maturation and KSR2 mediates SF3B1-driven proliferation. a qRT-PCR and western blot analysis to detect
mRNA (upper panel) and protein levels (lower panel) of KSR2 in Ishikawa and AN3CA cells transfected with SF3B1 or Control siRNA. b Schematic
representation of strategy to identify intron–exon (unspliced, pre-mRNA) and exon–exon (spliced, mature RNA) junction sites using qRT-PCR. Speciﬁc
primers designed are represented by the two arrow pairs, illustrating their approximate locations. c Relative levels of unspliced and spliced KSR2
transcripts and their ratio in Ishikawa and AN3CA cells transfected with Control or SF3B1 siRNA. β-actin was used for normalization. Data are
presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. d Conﬁrmation of SF3B1 knockdown and KSR2 overexpression in Ishikawa
cells co-transfected with SF3B1 siRNA or KSR2 plasmids. e Cell proliferation assay in Ishikawa cells co-transfected with SF3B1 siRNA or KSR2 plasmids at
indicated times. f Schematic illustration of the hypothesis showing how overexpressed SF3B1 might promote endometrial cancer progression by
generating transcript variants and mature mRNAs.

Interestingly, a recent report suggested that aberrant
splicing by mutant SF3B1 altered the transcriptome,
proteome, and metabolome of human cells and caused
mis-splicing of various associated metabolic genes44.
Here, we also found SF3B1 transcriptome enriched with
several metabolic process, suggesting a possible role for
SF3B1 in metabolic programming in cancers. It is wellrecognized that SF3B1 regulate alternative splicing of
several crucial genes involved in cell survival pathways
implying its oncogenic potential in promoting tumorigenesis24,40,41. Consistently, we found wide scale disruption of alternative splicing across the transcriptome,
suggesting that SF3B1-driven alternative splicing has a
pathogenic signiﬁcance in endometrial cancer. Interestingly, we identiﬁed differential exon usage in one of the
Ofﬁcial journal of the Cell Death Differentiation Association

important small nucleolar RNAs (snoRNAs), the SNHG4.
Previous studies demonstrated the overexpression of
numerous snoRNAs in several cancers and their role in
promoting proliferation, cell cycle progression, invasion,
and metastasis45–47. Therefore, investigating the role of
snoRNAs in endometrial cancer is quite intriguing;
however, in-depth functional studies are required to dissect the role of such potential alternative spliced variants
in endometrial cancer tumorigenesis.
Several lines of evidence suggest that PTEN, a tumor
suppressor gene is frequently mutated in −30 to 50% of
endometrial cancers48–50. Increased SF3B1 levels in tumors
originated due to PTEN loss suggest that overexpression of
SF3B1 coupled with PTEN loss might drive the endometrial cancer progression. However, more in-depth
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studies are required to test whether SF3B1 overexpression
and PTEN loss are mutually exclusive in endometrial
cancers. Importantly, these studies might provide molecular underpinnings of endometrial cancer initiation and
progression.
Previous studies have shown that attenuation in splicing
factor-driven RNA maturation promotes tumorigenesis
through the accumulation of pre-mRNAs51,52. We found
decreased expression of KSR2 due to impairment in
SF3B1-mediated mRNA maturation and KSR2 partially
contributes to SF3B1 pro-proliferative function. Given,
multitude of genes impacted by mis-splicing due to splicing factor dysfunctions, the downstream functional
impact is unlikely due to the altered splicing of a single
gene variant. Instead, splicing factor deregulation may
cause broad splicing aberrations resulting in induction of
distinct transcriptional signature(s) that promote tumor
progression. Thus, the partial contribution of KSR2 to
overall SF3B1 function in our study indicates that SF3B1
exerts its functions through numerous downstream
effector genes. For example, we found many of the SF3B1regulated genes associated with metabolic process (Supplementary Table 2). Therefore, future studies dovetailing
transcriptomics and metabolomics may provide better
understanding on the functional role of SF3B1 in endometrial cancer progression.
SF3B1 is a target of PLAD-B, a natural product with
anti-tumor activity in both cancer cell lines and mouse
xenograft models41,53,54. By impairing the binding of the
spliceosome to the branch sequence, PLAD-B causes an
accumulation of unspliced mRNA in cells, resulting in
reduced viability35,55. Here, we found that PLAD-B
decreased endometrial cancer cell proliferation, migration, and invasion in vitro. Furthermore, we found that
PLAD-B reduced the endometrial cancer burden in our
orthotopic endometrial cancer model, suggesting that
PLAD-B, or a derivative, might be a viable therapeutic
with which to treat endometrial cancer.
In summary, we report that SF3B1 plays an important
role in endometrial cancer initiation and progression
possibly through regulating KSR2 mRNA maturation.
Thus, uncovering the precise role of SF3B1 in the progression of endometrial cancer will increase our knowledge of spliceosome function in endometrial cancer.
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